Consistently, treatment of cancer cells with EGFR/HER2-tyrosine kinase inhibitors (EGFR/HER2-TKI; e.g. gefitinib and lapatinib) or anti-ErbB-2 monoclonal antibodies (e.g. trastuzumab) induces cell proliferative arrest and/or cell death, and this has been shown to be mediated through the PI3K/Akt/FOXO3 signalling axis [31, 126–132]. This evidence concerns the gene FOXO3 and cancer.